Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
24-week randomized double-blind placebo-controlled trial of flibanserin in premenopausal European women with hypoactive sexual desire disorder
2007-000032-68Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of flibanserin in hypoactive sexual desire disorder (HSDD) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Change from baseline in frequency of satisfying sexual events. Started Mar 2007; status: completed.
02
Drugs
flibanserin
03
Conditions
hypoactive sexual desire disorder (HSDD)
Beyond the preview
Go deeper on 2007-000032-68.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000032-68.